Cara Therapeutics, INC 8-K filings
Cara Therapeutics announced a streamlined operating plan, including a 70% workforce reduction, after discontinuing a clinical program for notalgia paresthetica.
Cara Therapeutics has halted its clinical program for oral difelikefalin in notalgia paresthetica after the drug failed to show meaningful clinical benefit in a Phase 2/3 study.
8-K: Cara Therapeutics Increases Authorized Shares and Approves Reverse Stock Split at Annual Meeting
Cara Therapeutics' stockholders approved an increase in authorized shares and a potential reverse stock split at the company's annual meeting on June 4, 2024.
Cara Therapeutics reported its first quarter 2024 financial results and announced that topline efficacy and safety results from the KOURAGE 1 Part A study are expected by the end of the second quarter of 2024.
Cara Therapeutics' Chief Medical Officer, Dr. Joana Goncalves, has announced her resignation, effective April 16, 2024, to pursue another opportunity.
Cara Therapeutics is focusing on its late-stage notalgia paresthetica (NP) clinical program and has extended its cash runway into 2026.
Cara Therapeutics has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement, potentially leading to delisting if not rectified.
Cara Therapeutics is prioritizing its notalgia paresthetica program, discontinuing its chronic kidney disease program, reducing its workforce, and extending its cash runway into 2026.